摘要
目的观察穿心莲酸对高脂饮食诱导的ApoE^(−/−)小鼠动脉粥样硬化模型的干预作用。方法将高脂饲料喂食诱导动脉粥样硬化模型的ApoE^(−/−)小鼠随机分为模型组、瑞舒伐他汀组、穿心莲酸高、中、低剂量组,每组各10只,另取10只C57BL/6小鼠作为对照组,给药后检测小鼠血清血脂水平,观察主动脉病理形态变化,采用Westernblot法检测小鼠主动脉NLRP3相关通路蛋白的表达。结果高、中剂量的穿心莲酸均能显著降低高脂喂食诱导的动脉粥样硬化模型ApoE^(−/−)小鼠的血清胆固醇(TC)及低密度脂蛋白(LDL-C)水平,升高高密度脂蛋白(HDL-C)水平(P<0.05),主动脉病理切片油红O染色显示穿心莲酸高剂量组主动脉壁各层正常,斑块较少,脂质浸润明显减轻,高、中剂量穿心莲酸均可降低主动脉NLRP3、caspase-1、IL-1β和IL-18蛋白表达(P<0.05)。结论穿心莲酸可能通过调控NLRP3通路减轻AS小鼠主动脉病变。
Objective To observe the effects of andrographolic acid on NLRP3 pathway in atherosclerosis model mice induced by high fat diet.Methods ApoE^(−/−)mice with high fat diet were randomly divided into model group,rosuvastatin group,andrographolic acid high dose group,middle dose group and low dose group,with 10 mice in each group,another 10 C57BL/6 mice were used as control group.After administration,serum lipid level,and pathological changes of the aorta were detected.The protein expressions of NLRP3,caspase-1,IL-1β,IL-18 in the aorta were detected by Western blot.Results Middle and high doses of andrographolic acid could significantly reduce the levels of serum TC and LDL-C,and increase the level of HDL-C in ApoE^(−/−)mice with high fat diet(P<0.05).The oil red O staining of aortic pathological sections showed that the aorta wall in the high dose group was normal,with fewer plaques and significantly reduced lipid infiltration.High and middle doses of andrographolic acid decreased NLRP3,Caspase-1,IL-1βand IL-18 protein expression in aorta(P<0.05).Conclusion Andrographolic acid may reduce aortic lesions in AS mice by regulating NLRP3 pathway.
作者
赖亦静
黄雪君
李钰婷
彭莎
江洁怡
陈玉兴
蔡大可
甘海宁
LAI Yijing;HUANG Xuejun;LI Yuting;PENG Sha;JIANG Jieyi;CHEN Yuxing;CAI Dake;GAN Haining(The Fifth Clinical Medical College,Guangzhou University of Chinese Medicine,Guangzhou 510405,China;Guangdong Second Traditional Chinese Medicine Hospital(Guangdong Province Engineering Technology Research Institute of TCM),Guangzhou 510095,China;Guangdong Provincial Key Laboratory of Research and Development in TCM,Guangzhou 510095,China)
出处
《广东药科大学学报》
CAS
2021年第6期84-88,共5页
Journal of Guangdong Pharmaceutical University
基金
广东省医学科学技术研究基金(A2019308)。
